Countable Labs has raised $26m to advance the development and commercialisation activities for its single-molecule polymerase chain reaction (PCR) technology. The California-based company's financing ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Countable Labs (formerly Enumerix) enters the genomics market with the launch of Countable PCR, redefining what’s possible with PCR for rare event detection. By ...
Countable Labs, the developer of Countable PCR, a breakthrough single-molecule PCR technology redefining how science measures ...
Leading life sciences investors ARCH Venture Partners, F-Prime Capital, and Primer Ventures fuel company's expansion into cell and gene therapy, oncology, and molecular diagnostics PALO ALTO, Calif.-- ...
Countable Labs Brings Innovative, Single-Molecule, Counting-Based PCR to European Markets with CE Mark Clearance Countable PCR delivers single-molecule precision for Europe's most demanding ...
Countable Labs, the developer of Countable PCR, announced a co-marketing agreement with Promega. The agreement brings together the capabilities of the Promega Maxwell® System for nucleic acid ...
DNA and RNA are central to laboratory and clinical research, where quantifying their abundance is key to applications such as gene expression analysis, cell and gene therapy development, and ...
Polymerase chain reaction (PCR) is a workhorse for quantifying nucleic acids across a range of applications, including biomanufacturing and clinical research for viral titer, vector copy number, ...
PALO ALTO, Calif. & MADISON, Wis., June 25, 2026--(BUSINESS WIRE)--Countable Labs, the developer of Countable PCR, a breakthrough single-molecule PCR technology redefining how science measures biology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results